Browse TAF8

Summary
SymbolTAF8
NameTAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Note=Localized in the cytoplasm and transported from the cytoplasm to the nucleus in some cells, possibly depending on the functional or developmental state of the cell.
Domain PF07524 Bromodomain associated
PF10406 Transcription factor TFIID complex subunit 8 C-term
Function

Transcription factor TFIID is one of the general factors required for accurate and regulated initiation by RNA polymerase II. Mediates both basal and activator-dependent transcription. Plays a role in the differentiation of preadipocyte fibroblasts to adipocytes, however, does not seem to play a role in differentiation of myoblasts. Required for the integration of TAF10 in the TAF complex. May be important for survival of cells of the inner cell mass which constitute the pluripotent cell population of the early embryo (By similarity).

> Gene Ontology
 
Biological Process GO:0001701 in utero embryonic development
GO:0001824 blastocyst development
GO:0001832 blastocyst growth
GO:0001833 inner cell mass cell proliferation
GO:0009301 snRNA transcription
GO:0016073 snRNA metabolic process
GO:0032507 maintenance of protein location in cell
GO:0034504 protein localization to nucleus
GO:0042795 snRNA transcription from RNA polymerase II promoter
GO:0045185 maintenance of protein location
GO:0045444 fat cell differentiation
GO:0045598 regulation of fat cell differentiation
GO:0051235 maintenance of location
GO:0051457 maintenance of protein location in nucleus
GO:0051651 maintenance of location in cell
GO:0072595 maintenance of protein localization in organelle
GO:0098781 ncRNA transcription
Molecular Function GO:0046982 protein heterodimerization activity
Cellular Component GO:0000428 DNA-directed RNA polymerase complex
GO:0005667 transcription factor complex
GO:0005669 transcription factor TFIID complex
GO:0016591 DNA-directed RNA polymerase II, holoenzyme
GO:0030880 RNA polymerase complex
GO:0044798 nuclear transcription factor complex
GO:0055029 nuclear DNA-directed RNA polymerase complex
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0090575 RNA polymerase II transcription factor complex
> KEGG and Reactome Pathway
 
KEGG hsa03022 Basal transcription factors
Reactome R-HSA-74160: Gene Expression
R-HSA-6807505: RNA polymerase II transcribes snRNA genes
Summary
SymbolTAF8
NameTAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TAF8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTAF8
NameTAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TAF8 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.66 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTAF8
NameTAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TAF8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0710.744
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3120.777
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1110.903
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0280.923
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0870.967
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0470.986
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1720.526
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3650.779
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0430.977
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4410.69
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5250.755
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0670.255
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TAF8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTAF8
NameTAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TAF8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTAF8
NameTAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TAF8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TAF8.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTAF8
NameTAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TAF8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTAF8
NameTAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TAF8 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTAF8
NameTAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TAF8 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTAF8
NameTAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TAF8 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.